Vitatron
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's Netherlands-based organization announces commercial release of the Vitatron Selection AFm monitoring pacing system in the U.S. Sept. 14. The device incorporates Beat-to-Beat mode switching and dual sensor physiologic rate response pacing therapies that help reduce arrhythmia symptoms, the company explains. The system continuously monitors the patient's rhythm 24 hours a day and stores atrial arrhythmia information, including the number and length of episodes that enables physicians to target atrial fibrillation onset